Kornimate/medical-research-clean huggingface dataset:
safety and efficacy study of topical ranpirnase to treat genital warts (hpv)

Conditions: Condylomata Acuminata; Papillomavirus Infections; Sexually Transmitted Diseases

Summary: ranpirnase in topical formulation is an antiviral drug being evaluated for the topical treatment of anogenital warts. the aims of this study is to evaluate the efficacy and safety of a topical formulation of ranpirnase in subjects with genital warts.

the study consists of the evaluation of 4 weeks exposure to the study product; designed as randomized, double blinded, against vehicle to study the effects of 1 mg/ml concentration of ranpirnase on anogenital warts. the dermal reaction are scored on a scale that describes the amount of erythema, edema, and other features indicative of irritation. the clinical response are be scored on the basis of the percentage of the reduction of the lesions in size and number.

Eligibility criteria:
inclusion criteria: * diagnosis of external genital / perianal warts with at least 2 warts and no more than 30 lesions * accept to follow study instructions / signature of ic * abstain from sexual intercourse for 6 hours after applying the study product during the time of the study. exclusion criteria: * any topical and/or destructive treatments for external genital warts within 4 weeks (within 12 months for imiquimod and within 12 weeks for sinecatechins) prior to enrollment (i.e., the randomization visit) * non pregnant. for women in reproductive age it would be required pregnancy test, and the use of double barrier contraceptives. * any of the following conditions: * known allergy to the study product * internal (rectal, urethral) warts that required or were undergoing treatment; * a dermatological disease (e.g., psoriasis) or skin condition in the area, which may interfere with the evaluation. * imiquimod 5% cream (aldara®) * any marketed or investigational hpv vaccines * sinecatechins (veregen) * interferon or interferon inducers * cytotoxic drugs * immunomodulators or immunosuppressives * oral or parenteral corticosteroids (inhaled/intranasal steroids are permitted) * oral antiviral drugs (with the exception of haart, oral acyclovir and acyclovir related drugs) for suppressive or acute therapy herpes; or oseltamivir for prophylaxis or for influenza) * topical antiviral drugs (including topical acyclovir and acyclovir related drugs) in the areas under treatment * podophyllotoxin/podofilox in the treatment areas * any topical prescription medications in the treatment areas * dermatologic procedures or surgery in the treatment areas
the application and evaluation of ehealth literacy (ehl) concept

Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Diseases; Cardiovascular Diseases

Summary: this study aims to explore the effectiveness of experience learning program of ehealth care to improve the chronic patients' ehl in engaging with the ehealth care system on the indicators on ehealth literacy, patient health engagement, e-health usage status among chronic disease patients included type 2 diabetes patients, chronic kidney disease, and cardiovascular diseases.

chronic diseases are irreversible that incurs considerable medical and economic costs. even if the government and medical health care system make an effort to improve care and recommend e-health care, the incidence and prevalence rates of chronic diseases have not decreased but increased, and participants have even become the main cause of kidney disease. technology and daily life has become more inseparable, which also led to the change of the traditional face to face health care model. the chronic disease care is gradually transitioning into the smart ehealth care era, patients are in need of learning how to face innovative ways of using care and resources. ehealth literacy (ehl)is the essential element that determines if patient can adapt to the rapidly changing health care system. due to the disciplinary integration of medical and technology, ehealth care provides continuous care for patients. but, it is still necessary to return to patient-centered care thinking and improving patients' knowledge and ability to use ehealth care technology. this can be applied to disease care, and implemented for daily self-health management. therefore, this study explores the effects of intervention and the learning process and experience of patients through an experience learning program of ehealth care.

Eligibility criteria:
inclusion criteria: * diagnosed as a type 2 diabetes patients, chronic kidney disease, and cardiovascular diseases more than three months. * at least 20 years old, with clear consciousness and able to communicate in mandarin or taiwanese. * possess a mobile phone or tablet with internet capabilities. * consent to participate in this research and be willing to sign a consent form. exclusion criteria: * suffering from serious diseases, such as: general paralysis, mental disorders, cognitive function abnormalities, etc. * those who cannot communicate in mandarin or taiwanese. * those who refuse to participate in this research.

Keywords: chronic disease ehealth literacy patient engagement experience learning theory self-management empowerment ehealth care
comparison of blue light filter feature and blue blocking lenses in digital device users with dry eye patients

Conditions: Dry Eye Syndromes

Summary: comparing blue light filter feature and blue blocking lenses for dry eye patients prolonged screen time can exacerbate dry eye symptoms.

two solutions, blue light filter software and blue blocking lenses, aim to reduce eye strain. blue light filter software adjusts screen color temperatures, reducing blue light emission. blue blocking lenses provide a physical barrier, blocking blue light from reaching the eyes.

Eligibility criteria:
inclusion criteria: * adults aged 12-34 * spend at least 4 hours per day on digital devices. * experience dry eye symptoms. * willing to participate in the study and provide informed consent. exclusion criteria: * pre-existing eye conditions (e.g., cataracts, glaucoma). * wear contact lenses. * have undergone eye surgery. * are pregnant or breastfeeding.
nutrition education on the metabolic syndrome of subjects who are frequently eating out

Conditions: Metabolic Syndrome

Summary: the project is aimed at investigating the effect of nutrition education on knowledge, attitude and practice (kap)of subjects who are frequently eating out, and the effect on metabolic parameters.

the project is aimed at investigating the dietary structure and frequencies of eating out via a cross-sectional study, on the basis of which a randomized, parallel controlled trials is to be carried out.the purpose is to evaluate the effect on metabolic parameters. hypotheses to be tested:nutrition education has the effect of improving the metabolic parameters of subjects who are frequently eating out.

Eligibility criteria:
inclusion criteria: * shanghai urban citizens * male or female 18 to 25 years of age; * frequently eat out(eat out 3 or more times per week); * clinical diagnosis of metabolic syndrome(meet 3 or more diagnostic criteria); a. abdominal obesity: waist circumference\>90cm ( m ), and\>85cm( f ); b. dyslipidemia:triglyceride≥1.7mmol/l; c. hdl-c \< 1.04mmol/l; d. hypertension: blood pressure≥ 130/85mm hg ( or have been diagnosed hypertension); e. hyperglycemia : fpg≥6.1mmol/l and ( or ) 2-hour postprandial blood glucose≥7.8mmol/l and ( or ) have been diagnosed with diabetes; * signed written informed consent ; * can attend lectures. exclusion criteria: * pregnant woman; * temporary resident population; * participating in another clinical trial 6 months before randomization.

Keywords: metabolic syndrome eating out of home nutrition education
aza combined with nac for pit after hsct

Conditions: Thrombocytopenia, Isolated; Stem Cell Transplant Complications

Summary: prolonged isolated thrombocytopenia (pit) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. recombinant human thrombopoietin (rhtpo) is the main therapy in clinical practice, but remains low efficiency for pit. demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (mds) and acte myeloid leukemia (aml). in addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for pit in early clinical trials with elusive mechanism. preliminary experiments revealed that pit was associated with abnormality of oxidation microenvironment, and n-acetyl-l-cysteine (nac) was the most commonly used antioxidant. therefore, the investigators have been wondering whether azacitidine in combination with nac could improve pit post hsct and explore the possible mechanism of it.

prolonged isolated thrombocytopenia (pit) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. recombinant human thrombopoietin (rhtpo) is the main therapy in clinical practice, but remains low efficiency for pit. demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (mds) and acte myeloid leukemia (aml). in addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for pit in early clinical trials with elusive mechanism. preliminary experiments revealed that pit was associated with abnormality of oxidation microenvironment, and n-acetyl-l-cysteine (nac) was the most commonly used antioxidant. furthermore, aza had shown its potential in immune regulation. therefore, the investigators have been wondering whether azacitidine in combination with nac could improve pit post hsct and explore the possible mechanism of it.

Eligibility criteria:
inclusion criteria: * platelet count ≤ 30 × 10\^9/l persistently at day 60 post-hsct or later; * neutrophil and hemoglobin were well recovered; * full donor chimerism was achieved; exclusion criteria: * patients with malignancy relapse; * active infections; * grade ⅲ-ⅳ acute graft-versus-host disease or severe chronic graft-versus-host disease according to national institute of health criteria; * severe organ damage; * thrombosis requiring treatment;

Keywords: azacitidine n-acetyl-l-cysteine prolonged isolated thrombocytopenia hematopoietic stem cell transplantation
impact of decision aids in urogynecology

Conditions: Pelvic Organ Prolapse; Stress Urinary Incontinence; Overactive Bladder

Summary: to evaluate how patient knowledge and confidence in decision making can be impacted by shared decision making in common urogynecology conditions.

the investigators will enroll patients seeing a specialist to discuss treatment of pelvic organ prolapse, overactive bladder and stress urinary incontinence in this pilot study. the study will evaluate the feasibility and acceptability of three decision aids designed to promote shared decision making conversations for these three condition. the investigators use a quasi-experimental design in which the investigators first enroll patients in the control arm and measure their outcomes. then, the investigators enroll patients into the intervention arm and measure their outcomes. the investigators estimate that it will take about one month to recruit the control arm and one month to recruit the intervention arm. patients will be surveyed after the clinic visit with a specialist and surveys will assess patients' knowledge, treatment preferences, shared decision making, decisional conflict and acceptability of the tool. a clinician survey will be administered and completed after each patient visit, that details how the physician felt about the length of the visit, how informed the patient was, and how far along they may be with their decision.

Eligibility criteria:
inclusion criteria: * adults 18-95 years only * english speaking * pelvic organ prolapse defined by noticeable (to the patient) vaginal bulging * symptoms of stress urinary incontinence (cough, sneeze, laugh, exercise) * presenting for initial consultation for either of the above symptoms exclusion criteria: * primary complaint is not vaginal bulging or stress urinary incontinence * prior surgery for pelvic organ prolapse or any incontinence procedure

Keywords: shared decision making
randomized trial of gemcitabine/cisplatin + pf-3512676 vs gemcitabine/cisplatin alone in patients with advanced nsclc

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: to assess the efficacy and safety of pf-3512676 administered in combination with gemcitabine/cisplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (nsclc) and to compare it to the efficacy and safety of gemcitabine/cisplatin alone.

pf-3512676 dosing was stopped 20 june 2007 in response to dsmc recommendation to close the trial, citing lack of efficacy concerns as the primary reason with a safety issue (thrombocytopenia) also contributing to the decision. subjects were allowed to complete standard of care treatment/survival follow-up. data collection was completed on 25 june 2008.

Eligibility criteria:
inclusion criteria: * advanced non-small-cell lung cancer (nsclc) stage iiib with pleural effusion or stage iv * no prior systemic treatment for non-small-cell lung cancer (nsclc) with chemotherapy, immunotherapy, biologic response modifiers or other investigational drugs * eastern cooperative oncology group performance status (ecog ps) 0 or 1 exclusion criteria: * small cell or carcinoid lung cancer * known central nervous system (cns) metastasis * pre-existing auto-immune or antibody mediated diseases

Keywords: advanced carcinoma, non-small cell lung, phase iii, gemcitabine, gemzar, cisplatin, platinol, pf-3512676, immunotherapy, immune modulator
postdural puncture headache relief with aminophylline and spgb

Conditions: Anesthesia

Summary: the purpose of the study is to compare sphenopalatine ganglion block (spgb) and aminophylline in the efficacy and safety management of pdph.

postdural puncture headache (pdph) is a severe and debilitating complication after regional anesthesia in the obstetric population; the gold standard treatment for pdph is epidural blood patch, which is an invasive and risky procedure. the trans-nasal sphenopalatine ganglion (spg) block and intravenous aminophylline are promising options for pdph. so the investigators designed this randomized, double-blind study to compare sphenopalatine ganglion block (spgb) and aminophylline in the efficacy and safety management of pdph.

Eligibility criteria:
inclusion criteria: * 18 - 40 years old female. * asa i -ii according to the american society of anesthesiologists. * spinal anesthesia with 22g quincke needle for cesarean section. * pdph was defined according to the international classification of headache disorders, 3rd edition criteria (ichd-3) as: * headache occurring within 5 days of a lumbar puncture. * orthostatic headache that significantly worsens soon after sitting upright or standing and/or improves after lying horizontally usually accompanied by neck pain, tinnitus, changes in hearing, photophobia, and/or nausea. * exclusion of other causes such as hypertension, preeclampsia, tension headache, migraine, etc. exclusion criteria: * a history of headaches that could interfere with the pdph diagnosis, * a history of central nervous system diseases, including intracranial hemorrhage, seizures, intracranial hypertension, or hydrocephalus * a history of cardiovascular diseases, including coronary heart disease, arrhythmias, or hypertension. * a history of allergy to or any contraindication for using aminophylline. * coagulopathy. * nasal septal deviation, polyp, or nasal bleeding. * general anesthesia after failed spinal anesthesia.
chronic suppurative otitis media microbiology

Conditions: Otitis Media, Suppurative Chronic; Cholesteatoma; Microbial Colonization

Summary: this study is planned to reveal the microbiological agents and drug sensitivities to these agents in patients diagnosed with chronic suppurative otitis media who complain of ear discharge.

patients with complaints of ear discharge and who were diagnosed with chronic suppurative otitis media will be included in the study. patients will be divided into two groups: csom with cholesteatoma and csom without cholesteatoma. one hundred ten patients from each group will be included in the study. after a comprehensive medical history is taken for each patient, the patient's external auditory canal will be cleaned with sterile aspirators. a sterile culture will be taken from the discharge of the ear and sent to microbiology. with the data obtained from microbiological examination, pathogens will be classified as gram-positive, gram-negative, anaerobic, and fungal and examined according to monomicrobial and polymicrobial growth. antibiotic susceptibility tests will be conducted to determine the effectiveness of antibiotics against the bacteria causing the infection.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with chronic suppurative otitis media 2. patients over 18 years of age exclusion criteria: 1. chronic nonsuppurative otitis media patients 2. patients diagnosed with external ear canal/middle ear malignancy 3. patients who take immunosuppressive drugs 4. immunosuppressive patients 5. patients who used antibiotics (topical-systemic) in the last week

Keywords: chronic suppurative otitis media cholesteatoma ear discharge
intelligent sports injury prevention and training system

Conditions: Sport Injury

Summary: sports injuries are a very important issue for baseball players. previous studies have found that the incidence of sports injuries faced by baseball players is continuously increasing. sports injury rates in professional baseball, high school baseball, and college baseball players were as high as 3.6, 4.6, and 5.8 per 1,000 players, respectively. the main cause of many pitching injuries is attributed to a large number of repetitive pitches. to avoid sports injuries, it is necessary to know how to assess the risk of injury caused by repetitive pitching. throwing is a fairly complex action that requires the coordination of the entire body. it is critical to investigate the biomechanical changes of players in order to effectively analyze such complex movements.


Eligibility criteria:
inclusion criteria: * healthy baseball pitchers * age between 18\~55 years old exclusion criteria: * surgery history in pitching arm * musculoskeletal disease * neuromuscular disease
iodine supplementation in obesity

Conditions: Iodine Deficiency; Subclinical Hypothyroidism

Summary: the study hypothesis is that iodine supplementation will lower serum tsh and leptin concentrations and thereby improve the lipid and glucose profile.

the study will be a double blind, placebo controlled intervention study in obese women living in the atlas foot mountains in morocco, an iodine deficient area. eligible subjects will be randomized into intervention and control group and will receive the respective supplement for 6 months. at baseline, midpoint and endpoint anthropometric as well as metabolic profile will be assessed. a health questionnaire will further be administered monthly when the tablets for the following month are distributed. urine samples to determine iodine status will also be collected monthly.

Eligibility criteria:
inclusion criteria: * women of reproductive age (20 to 50 years) * body mass index 27 to 40 kg/m2 * having received oral and written information about the aims and procedures of the study * willing to comply with the study procedure * having provided oral and written informed consent exclusion criteria: * chronic disease or gastrointestinal disorders * nodular goiter * regular use of medication (except oral contraceptives) * pregnancy or lactation * subject who cannot be expected to comply with study protocol

Keywords: iodine thyroid hormones obesity tsh dyslipidemia insulin resistance
the detection of cell-in-cell structure (cics) in patients with breast cancer undergoing neoadjuvant chemotherapy

Conditions: Breast Neoplasms

Summary: breast cancer is the most common malignant tumor in women worldwide and neoadjuvant therapy has been the standard care for local advanced breast cancer. moreover, neoadjuvant therapy undoubtedly provides an ideal model to evaluate the response to therapy. cell-in-cell structures (cics) refer to the presence of one or more cells inside host cell, which generally leads to the death of inner cells. notably, established evidences indicated that cics were present in breast cancer and tend to impact patient survival. however, whether cics profile could predict efficacy of therapy remains unclear. in this prospective cohort study, the cics number and profile will be detected in tumor tissue before and after the neoadjuvant therapy. then the association between cics number including dynamic changing and response rate will be explored.


Eligibility criteria:
inclusion criteria: * age 18-65, female; * pathological biopsy confirmed invasive ductal carcinoma; * karnofsky performance status (kps)≥ 60, expected survival ≥4 months; * locally advanced breast cancer (her2-positive disease and tnbc, ≥ct1c or ≥cn0； her2-negative，hr positive disease，≥ct2 or ≥cn1；large primary tumor relative to breast size in a patient who desires breast conservation) ; * according to the recist1.1 standard, at least one measurable lesion exists; exclusion criteria: * pregnant or lactating women; * left ventricular ejection fraction less than 50%; * history of malignant tumor and concurrent occurrence of other tumors; * serious medical pathology, such as congestive heart failure; unstable angina; uncontrolled high risk arrhythmias, and other serious illness or medical condition that may interfere with the study; * refuse to participate in the study.

Keywords: breast neoplasms cell-in-cell structures neoadjuvant therapy
ward-home - continuous monitoring of vital parameters after discharge

Conditions: Vital Sign; Clinical Deterioration

Summary: the current pilot study aims to investigate the feasibility of wireless, continuous monitoring of patients in the days around discharge after an acute medical hospitalization, as well as occurrence of deviating vital signs in this patient group.

the healthcare system is challenged by an aging patient population with chronic diseases, and acute admissions must be housed in hospitals with fewer beds and less staff resources. this increases the need for earlier discharge and for treatment shifted to the patients' own home. furthermore, the transition from the hospital to the home setting is one of potential hazard, due to the lack of observation and intervention possibilities. this pilot study aims to investigate the feasibility of wireless, continuous monitoring of patients in the days around discharge after an acute medical hospitalization, as well as occurrence of deviating vital signs i in the patients' own homes during the first days after discharge.

Eligibility criteria:
inclusion criteria: adult patients (≥18 years) admitted with an acute medical disease and scheduled for discharge to their own homes within five days from inclusion. exclusion criteria: * allergy to plaster, plastic, or silicone. * a pacemaker or implantable cardioverter defibrillator (icd) device. * if the patient was deemed not able to open the front door when visited by the investigator. * inability to give informed consent.